Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
* Mondays: BioBucks: Stock Analysis & Biotech Catalysts
* Wednesdays: CRISPR Corner: Monthly gene editing news
* Thursdays: Insiders Track: Public & Private Biotech Markets
* Fridays: Sweat Equity: Your Weekly Biotech Fix
* Sundays: Building Biotech: Strategic Topics
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week, we dive into Epoch 39: Building Commercial Biotech Capability, where we explore a growing trend in the biotech industry. Increasingly, biotechs are finding themselves without pharma buyers, even when they have approved products. This shift is pushing companies to build their own commercial capabilities, navigating uncharted waters to bring their innovations to market independently. Join us as we unpack the challenges and opportunities of this evolving landscape!
Table of Contents:
[0:00] Intro
[1:15] NASH (mispronounced KNEE-ASH sorry!]
[1:40] Public biotech running short on cash
[2:35] Trends in new drug approvals coming from small biotech
[3:00] Madrigal Case Study
[4:30] Madrigal Commercialization tactics
[6:20] Why hasn’t Madrigal been acquire yet?
[10:00] The way forward
We also encourage you to check out the newsletter format of this discussion which goes into a bit more detail on specific tactics biotech companies can leverage to build commercial capabilities.
Thanks for reading BowTiedBiotech! Help us grow our community & earn free subscription to BowtiedBiotech - sharing is caring!
CONCLUSION
We hope you enjoyed our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
* LIFE SCIENCE CAREER GUIDE: REJECT REJECTION $22
* No More Small Molecule Medicines from Biotech?
* Epoch 42 - A Trojan Horse Enters With MASSIVE Biotech Implications
* Shaky Public Markets but Innovative Science Continues to Attract Capital
* Epoch 39 - Sorry But...Biotech Does Not Scale
* Epoch 35 - The Coming FED Pivot is NOT What You Expect
Get full access to BowTiedBiotech at bowtiedbiotech.substack.com/subscribe
Share this post